Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images

AEYE Health

Status: Completed

Conditions: Diabetes Mellitus; Diabetic Retinopathy

Treatments: Device: AEYE Software Device

Study type: Interventional

Funder types: Industry

Identifiers

NCT04612868

AEYE-DS-001

Details and patient eligibility

About

AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital fundus images using Artificial Intelligence (AI)-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.

Enrollment: 531 patients

Sex: All

Ages: 22+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥22
• Male or female
• Documented diagnosis of diabetes mellitus, meeting the criteria established by the American Diabetes Association (ADA) and World Health Organization (WHO).
• Understand the study and volunteer to sign the informed consent

Exclusion criteria

• Uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters.

• Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion.

• History of laser treatment of the retina or injections into either eye, or any history of retinal surgery.

• Currently participating in another investigational eye study and actively receiving investigational product for Diabetic Retinopathy (DR) or Diabetic Macular Edema (DME).

• Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation).

• Participant is contraindicated for imaging by fundus imaging systems used in the study:

  1. Participant is hypersensitive to light
  2. Participant recently underwent photodynamic therapy (PDT)
  3. Participant is taking medication that causes photosensitivity
  4. Participant has a history of angle-closure glaucoma or narrow anterior chamber angles

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

531 participants in 1 patient group

AEYE Software Device

Experimental group

Description:

An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.

Treatment:

Device: AEYE Software Device